Skip to main content
Premium Trial:

Request an Annual Quote

Epilepsy Foundation, Intellimedix, Pfizer Partner on Personalized Epilepsy Drug Discovery

NEW YORK (GenomeWeb) – The Epilepsy Foundation has teamed with Pfizer and Intellimedix to create a drug discovery platform targeted toward patients with genetic forms of epilepsy, the foundation said today.

The partners hope the drug screening platform will be used to create individualized treatments for people with Dravet Syndrome, a severe form of genetic epilepsy, and for other types of this disease for which there are only limited treatment options.

Atlanta-based Intellimedix uses next-generation sequencing, predictive analytics, and in vitro animal models to discover, develop, validate, and repurpose drugs and diagnostics for epilepsy and other neurological disorders.

"This collaboration has the potential to benefit all individuals and families living with epilepsy, especially the one-third of people with epilepsy who live with uncontrolled seizures despite all currently available therapies," Epilepsy Foundation President and CEO Philip Gattone said in a statement.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.